Filana Therapeutics, Inc.

As of June 30, 2026, Filana Therapeutics, Inc. carries a market capitalization of 50.43M, placing it among publicly traded companies globally. Its enterprise value stands at -21.94M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Filana Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, Filana Therapeutics, Inc. has 48.31M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Filana Therapeutics, Inc. maintains a current ratio of 2.08, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Filana Therapeutics, Inc. posted a negative return on equity (ROE) of -55.78, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -35.34, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 22.50, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Filana Therapeutics, Inc.'s stock has declined approximately 81.97% over the past 52 weeks. The 50-day moving average sits at 0.72, while the 200-day moving average is 1.20.

Over the twelve months ended June 30, 2026, Filana Therapeutics, Inc. generated - - in revenue and converted that into -37.01M in net income, yielding earnings per share of -0.77. EBITDA reached -39.38M, while operating income came in at -40.88M.

These figures are as of June 30, 2026. Total book value stands at 55.68M, with working capital of 38.13M providing operational flexibility.

Filana Therapeutics, Inc. produced -25.12M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -508,549.30 in capital expenditures, free cash flow totaled -25.63M - equivalent to -0.53 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -50.82: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.69, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Filana Therapeutics, Inc. shareholders.

Filana Therapeutics, Inc.'s most recent stock split took place on May 10, 2017 with a 7:1 split ratio.

As of June 30, 2026, Filana Therapeutics, Inc. has an Altman Z-Score of -7.06, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.